Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2
Buy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust Financials
Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial
Brainstorm Cell Analyst Ratings
Brainstorm Cell Analyst Ratings
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Brainstorm Cell Therapeutics (BCLI) and Agilon Health (AGL)
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Maxim Group Remains a Buy on Brainstorm Cell Therapeutics (BCLI)
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group